Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
NYS Entity Status
NYS Filing Date
JUNE 19, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - J&J PROFESSIONAL CONTRACTING, INC.
AROUND THE WEB
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
- Ask the NY Giants: Socks with Sandals?
Tuesday Sep 15, 2015
Professional athletes like members of the New York Giants are the inspiration for the latest (counterintuitive) high-fashion trend: wearing socks with sandals. Photo: Stu Woo/The Wall Street Journal
- biosimilar drugs can be a hard sell
By Jared S. Hopkins - Tuesday Aug 15, 2017
Part of the problem: a web of relationships between drug companies and insurers that shields incumbent drugs and often sidelines upstarts until the market becomes crowded.Pfizer said this month that Inflectra, its version of the blockbuster Johnson & Johnson rheumatoid arthritis drug Remicade, brought in $94 million in the second quarter.J&J spokeswoman Caroline Pavis said in a statement that Remicade is sold in a highly competitive market and that health plans decide on coverage.Doctors and patients tend to be loyal to innovative drugs that have worked well, payers are cautious in adopting alternatives, and Biosimilars can’t be swapped at the pharmacy because they aren’t identical to the drugs they are designed to replace.Remicade, known as infliximab and approved in the U.S. in 1998 for treating the digestive disorder Crohn’s disease, was cleared for rheumatoid arthritis a year later.J&J has exclusive contracts in nearly half its market, according to analyst Ronny Gal of Sanford Bernstein & Co., meaning payers agree to cover only Remicade for rheumatoid arthritis.When Sandoz released white-blood-cell booster Zarxio, the first biosimilar approved in the U.S., two years ago, it cost 15 percent less than Amgen’s Neupogen.[...] Neupogen has gradually lost its dominance, with sales sliding from $1.4 billion in 2013 to $765 million last year.[...] another similar drug, Granix by Teva Pharmaceutical, has been cleared, and Express Scripts last week became the second pharmacy-benefit manager to exclude Neupogen from its list of covered medicines.[...] Kay’s hospital found Inflectra cost $25 more than Remicade a vial, a discrepancy he attributes to pricing negotiations involving the supply chain.Makers of name-brand drugs once opposed biosimilars, citing safety among other concerns, but now say they have the manufacturing muscle and experience to produce and distribute the drugs.“For 20 years, until maybe this year, the brand industry’s position was, ‘Don’t take a biosimilar, it’s scary, it’s dangerous,’” said Bruce Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, which sells generics and is developing Biosimilars.
- Yahoo ordered to pay $5.5 million for busting March Madness deal
By Reuters - Monday Aug 21, 2017
(Reuters) — Yahoo Inc owes a prize promoter $5.5 million for backing out of a contract to pay $1 billion for predicting every winner in the 2014 NCAA men’s basketball tournament, and entering a similar contract with Quicken Loans Inc and Warren Buffett’s Berkshire Hathaway Inc, a court decided on Monday. The 5th U.S. Circuit […]
- Ryder Trucks Launches Campaign With 'Inc.'
Tuesday Sep 19, 2017
"The campaign underscores how truck owners are essentially dumping cash all over America's highways from all the hidden costs required in maintaining a private fleet," Ryder's Karen Jones tells"Marketing Daily."
- NY AG presses TransUnion, Experian for cybersecurity details
By DAVID KLEPPER, Associated Press - Tuesday Sep 19, 2017
ALBANY, N.Y. (AP) — New York Attorney General Eric Schneiderman is pressing TransUnion and Experian to explain what cybersecurity they have in place to protect sensitive consumer information following a recent breach at Equifax that exposed the data of 143 million Americans.In letters to executives at the two credit monitoring companies, the Democratic attorney general asked them to describe their existing security systems as well as what changes they've made since the Equifax cyberattack."The unprecedented data breach experienced by Equifax Inc.